Brief: Sun Pharma Advanced Research Gets Orphan Drug Designation From USFDA For SCO-088
July 8 (Reuters) - Sun Pharma Advanced Research Company Ltd
SPRC.NS :
* GETS ORPHAN DRUG DESIGNATION FROM USFDA FOR SCO-088 FOR
TREATMENT OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA
Source text: http://bit.ly/2S7FcHG
Further company coverage: SPRC.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sun Pharma Advanced Research
See all newsAdvisory: Alert incorrectly tagged to Sun Pharma Advanced Research withdrawn
Brief: Sun Pharma Advanced Research Appoints Anil Raghavan As MD And CEO Effective August 11
Brief: Sun Pharma Advanced Research Says Ocuvex Therapeutics Gets Complete Response Letter For PDP-716 NDA
India's Sun Pharma Advanced Research jumps after swinging to Q4 profit
Brief: Sun Pharma Advanced Research March-Quarter Consol Profit 17.61 Billion Rupees